Matrix, Gilead to develop generic Tenofovir for HIV/AIDS

By Lisa Kerner

Charlotte, N.C., Sept. 22 - Matrix Laboratories Ltd. signed a licensing agreement with Gilead Sciences, Inc. for the manufacture and sale of a generic version of Tenofovir Disoproxil Fumarate using Gilead's proprietary technology.

Under the agreement, Matrix has access to Gilead's technology for manufacture and sale of Tenofovir in 95 countries, including India. The Secunderabad, India-based active pharmaceutical ingredients manufacturers can also develop combination therapies using Tenofovir.

Tenofovir is a second-line treatment of HIV/AIDS recently endorsed by the World Health Organization as a first-line treatment as well.

Gilead is a biopharmaceutical company located in Foster City, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.